抗风湿治疗引发的严重感染：生物制剂的情况更糟吗？
Serious infections with antirheumatic therapy: are biologicals worse?
作者信息
Winthrop K L
机构信息
Division of Infectious Diseases, School of Medicine, Oregon Health Sciences University, 3375 SW Terwilliger Boulevard, Portland, OR 97239-4197, USA.
出版信息
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii54-7. doi: 10.1136/ard.2006.058503.
Abstract
This paper reviews the current evidence for the role of antirheumatic therapy in the development of serious infections in patients with rheumatoid arthritis (RA). Prednisone is clearly associated with increased infectious risk, but no definitive data link methotrexate to infection. Emerging data suggest that biological agents also pose increase infectious risk, particularly when used in combination with corticosteroids or methotrexate. Further research is needed in this important aspect of RA treatment. In the meantime, the author recommends that physicians should remain vigilant for serious infections in their patients with RA and use appropriate vaccines and screening procedures to mitigate their risk.
摘要
本文综述了抗风湿治疗在类风湿关节炎（RA）患者发生严重感染中所起作用的当前证据。泼尼松显然与感染风险增加相关，但尚无确凿数据表明甲氨蝶呤与感染有关。新出现的数据表明，生物制剂也会增加感染风险，尤其是在与皮质类固醇或甲氨蝶呤联合使用时。在RA治疗的这一重要方面仍需进一步研究。与此同时，作者建议医生应对其RA患者的严重感染保持警惕，并使用适当的疫苗和筛查程序来降低风险。
相似文献
1
Serious infections with antirheumatic therapy: are biologicals worse?抗风湿治疗引发的严重感染：生物制剂的情况更糟吗？
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii54-7. doi: 10.1136/ard.2006.058503.
2
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.在 CORRONA 注册研究中，甲氨蝶呤和肿瘤坏死因子拮抗剂与包括机会性感染在内的感染结局（包括感染性结局）风险的相关性。
Ann Rheum Dis. 2010 Feb;69(2):380-6. doi: 10.1136/ard.2008.089276. Epub 2009 Apr 8.
3
Advances in targeted therapy: safety of biological agents.靶向治疗的进展：生物制剂的安全性。
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii34-6. doi: 10.1136/ard.62.suppl_2.ii34.
4
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.《2006年关于治疗风湿性疾病生物制剂的最新共识声明》
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
5
Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection.阿那白滞素治疗施尼茨勒综合征和潜伏性结核感染的长期疗效与安全性。
Clin Exp Rheumatol. 2016 Mar-Apr;34(2):353. Epub 2016 Feb 26.
6
7
No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.使用日本健康保险数据库的流行病学研究：类风湿关节炎患者使用肿瘤坏死因子抑制剂和非肿瘤坏死因子抑制剂并无增加带状疱疹风险
Int J Rheum Dis. 2018 Sep;21(9):1670-1677. doi: 10.1111/1756-185X.13300. Epub 2018 Apr 17.
8
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.类风湿关节炎中抗TNF抗体治疗引发严重感染和恶性肿瘤的风险
JAMA. 2006 Nov 8;296(18):2203; author reply 2203-4. doi: 10.1001/jama.296.18.2203-a.
9
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.类风湿关节炎患者使用抗TNF抗体治疗时发生严重感染和恶性肿瘤的风险。
JAMA. 2006 Nov 8;296(18):2202; author reply 2203-4. doi: 10.1001/jama.296.18.2202.
10
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.类风湿关节炎患者接受抗TNF抗体治疗时发生严重感染和恶性肿瘤的风险。
JAMA. 2006 Nov 8;296(18):2201; author reply 2203-4. doi: 10.1001/jama.296.18.2201-a.
引用本文的文献
1
The Burden of Dental Infections Among Hospitalized Patients With Rheumatoid Arthritis: A Cross-Sectional Analysis of the National Inpatient Sample Database.类风湿性关节炎住院患者的牙科感染负担：全国住院患者样本数据库的横断面分析
Cureus. 2025 May 6;17(5):e83568. doi: 10.7759/cureus.83568. eCollection 2025 May.
2
The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases.新兴的自身免疫性疾病变革性疗法大爆发。
Front Immunol. 2020 Mar 31;11:472. doi: 10.3389/fimmu.2020.00472. eCollection 2020.
3
Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study.类风湿关节炎与非炎症性风湿性和肌肉骨骼疾病相比的严重感染风险：一项美国全国队列研究。
RMD Open. 2019 Jun 9;5(1):e000935. doi: 10.1136/rmdopen-2019-000935. eCollection 2019.
4
Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.阿片类镇痛药与类风湿关节炎患者严重感染风险：一项自身对照病例系列研究。
Arthritis Rheumatol. 2016 Feb;68(2):323-31. doi: 10.1002/art.39462.
5
Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.多发性硬化症患者的β干扰素疗法可提高调节性T细胞对T细胞免疫抑制的反应性。
Int J Mol Sci. 2015 Jul 17;16(7):16330-46. doi: 10.3390/ijms160716330.
6
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.托法替布对类风湿关节炎患者肺炎球菌和流感疫苗应答的影响。
Ann Rheum Dis. 2016 Apr;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191. Epub 2015 Mar 20.
7
"Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".使用抗肿瘤坏死因子α药物的类风湿关节炎患者的严重皮肤及软组织感染：一项巢式病例对照研究
BMC Infect Dis. 2013 Nov 11;13:533. doi: 10.1186/1471-2334-13-533.
8
Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.同床异梦：生物治疗时代的分枝杆菌和类风湿关节炎。
Nat Rev Rheumatol. 2013 Sep;9(9):524-31. doi: 10.1038/nrrheum.2013.82. Epub 2013 Jun 25.
9
Necrotizing fasciitis and septic shock related to the uncommon gram-negative pathogen Sphingobacterium multivorum.与罕见革兰氏阴性病原体多形拟杆菌相关的坏死性筋膜炎和感染性休克。
J Clin Microbiol. 2012 Jan;50(1):202-3. doi: 10.1128/JCM.05151-11. Epub 2011 Nov 9.
10
Rheumatoid lung disease.类风湿性肺病
Proc Am Thorac Soc. 2007 Aug 15;4(5):443-8. doi: 10.1513/pats.200703-045MS.
本文引用的文献
1
Glucocorticoid use, other associated factors, and the risk of tuberculosis.糖皮质激素的使用、其他相关因素与结核病风险
Arthritis Rheum. 2006 Feb 15;55(1):19-26. doi: 10.1002/art.21705.
2
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.类风湿关节炎的治疗与肺炎住院风险：与泼尼松、改善病情抗风湿药及抗肿瘤坏死因子治疗的关联
Arthritis Rheum. 2006 Feb;54(2):628-34. doi: 10.1002/art.21568.
3
Safety of extended treatment with anakinra in patients with rheumatoid arthritis.类风湿关节炎患者使用阿那白滞素延长治疗的安全性。
Ann Rheum Dis. 2006 Aug;65(8):1006-12. doi: 10.1136/ard.2005.048371. Epub 2006 Jan 5.
4
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.PREMIER研究：一项多中心、随机、双盲临床试验，对比阿达木单抗联合甲氨蝶呤与单用甲氨蝶呤或单用阿达木单抗治疗早期侵袭性类风湿关节炎且既往未接受过甲氨蝶呤治疗的患者。
Arthritis Rheum. 2006 Jan;54(1):26-37. doi: 10.1002/art.21519.
5
Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register.类风湿关节炎患者接受生物制剂和标准改善病情抗风湿药治疗的基线合并症水平：一项全国患者登记研究的结果
Ann Rheum Dis. 2006 Jul;65(7):895-8. doi: 10.1136/ard.2005.043158. Epub 2005 Dec 8.
6
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.甲氨蝶呤、肿瘤坏死因子阻滞剂及泼尼松龙对类风湿关节炎患者肺炎球菌多糖疫苗抗体应答的影响
Rheumatology (Oxford). 2006 Jan;45(1):106-11. doi: 10.1093/rheumatology/kei193. Epub 2005 Nov 15.
7
Infections in patients with rheumatoid arthritis treated with biologic agents.接受生物制剂治疗的类风湿关节炎患者的感染
Arthritis Rheum. 2005 Nov;52(11):3403-12. doi: 10.1002/art.21386.
8
Tuberculosis associated with therapy against tumor necrosis factor alpha.与肿瘤坏死因子α治疗相关的结核病
Arthritis Rheum. 2005 Oct;52(10):2968-74. doi: 10.1002/art.21382.
9
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.英国胸科学会关于评估开始抗TNF-α治疗患者的风险以及管理结核分枝杆菌感染和疾病的建议。
Thorax. 2005 Oct;60(10):800-5. doi: 10.1136/thx.2005.046797. Epub 2005 Jul 29.
10
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.类风湿关节炎患者的流感疫苗接种：包括肿瘤坏死因子α阻滞剂在内的改善病情药物的影响。
Ann Rheum Dis. 2006 Feb;65(2):191-4. doi: 10.1136/ard.2005.036434. Epub 2005 Jul 13.
Zotero 插件